SECONDARY MYELOFIBROSIS
Clinical trials for SECONDARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for SECONDARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New stem cell transplant approach aims to tame deadly bone marrow cancer
Disease control OngoingThis early-phase trial tests a reduced-intensity stem cell transplant using a half-matched donor and a drug called cyclophosphamide after the transplant to prevent rejection. The goal is to see if this approach is safe enough for patients with advanced myelofibrosis, a serious bo…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to prevent transplant complications in blood cancer patients
Disease control OngoingThis study tests whether adding the drug itacitinib to the usual two-drug regimen (cyclophosphamide and tacrolimus) can better prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD is a serious complication where donor cells at…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy for rare blood cancers put on hold
Disease control TerminatedThis phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a chemo drug help patients with rare bone marrow cancer?
Disease control OngoingThis phase II trial tests the drug decitabine in 21 patients with advanced myelofibrosis, a bone marrow cancer that causes scarring and anemia. The goal is to see if decitabine can improve blood counts and reduce the need for transfusions. Researchers are also monitoring side eff…
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can a cancer drug make stem cell transplants safer for myelofibrosis patients?
Disease control OngoingThis study tests whether giving the drug ruxolitinib before, during, and after a donor stem cell transplant can prevent graft-versus-host disease (GVHD) in people with myelofibrosis. GVHD is a serious complication where donor cells attack the patient's body. The trial enrolls 53 …
Matched conditions: SECONDARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Matched conditions: SECONDARY MYELOFIBROSIS
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC